INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, vol.11, no.4, pp.645-649, 2018 (SCI-Expanded)
AIM: To investigate the long-term visual and anatomical outcomes of patients who underwent intravitreal ranibizumab monotherapy to treat neovascular age-related macular degeneration (AMD) and followed-up for at least 2y.